DZIP3

DZIP3 is a multifunctional RNA-binding RING-H2 E3 ubiquitin ligase that couples mRNA regulation with chromatin modification and targeted protein degradation to control gene expression, cell-cycle progression, and innate immunity. Its lysine-rich region binds AU-rich elements in mRNA (e.g., Cyclin D1 3′ UTR), while its RING-H2 domain catalyzes mono- and polyubiquitination with distinct linkage specificities: monoubiquitination of H2AK119 in concert with the N-CoR/HDAC1/3 complex represses transcription by blocking FACT-dependent RNA Pol II elongation and reorganizes 3D chromatin at developmental genes (PMID:18206970, PMID:26568260); K63-linked ubiquitination stabilizes Cyclin D1 protein to drive G1 progression and tumor growth (PMID:33067265); and K48-linked ubiquitination targets substrates such as GBP5 and OCTN2 for proteasomal degradation (PMID:32796072, PMID:41566533). DZIP3 also functions as an ERα transcriptional coactivator in a ligase-activity-independent manner through interaction with CARM1 and GRIP1 (PMID:26505218), and scaffold lncRNAs (HOTAIR, LINCMD1) regulate its substrate access by bridging or sequestering it from specific targets (PMID:24326307, PMID:41566533).

1. 2003 High

   The initial characterization established that DZIP3 is a bifunctional protein possessing both RING-H2-dependent E3 ubiquitin ligase activity and RNA-binding capacity through a distinct lysine-rich region, resolving the basic enzymatic identity of the gene product.

   Evidence In vitro ubiquitylation assay with RING domain mutagenesis, RNA-binding domain mapping, and GFP imaging in mammalian cells

   PMID:12538761

   Open questions at the time

   • Physiological substrates and RNA targets were unknown
   • Whether the RNA-binding and ubiquitin ligase activities are functionally coupled was not addressed
   • Cytoplasmic localization to possible ER structures was not definitively resolved
2. 2008 High

   The discovery that DZIP3 monoubiquitinates H2AK119 as part of the N-CoR/HDAC1/3 repressive complex, blocking FACT recruitment and Pol II elongation at chemokine gene promoters, established its first physiological substrate and a direct chromatin-level mechanism of transcriptional repression.

   Evidence ChIP, Co-IP with N-CoR/HDAC complex, in vitro H2A ubiquitylation, knockdown with gene expression and Pol II elongation readouts in macrophages

   PMID:18206970

   Open questions at the time

   • How DZIP3 is recruited specifically to chemokine gene promoters versus other loci was unclear
   • Relationship between its RNA-binding function and chromatin role was unexplored
   • Whether this H2A ubiquitylation operates genome-wide or at select loci was unknown
3. 2013 High

   Demonstrating that the lncRNA HOTAIR scaffolds the DZIP3–Ataxin-1 interaction to promote ubiquitination and proteasomal degradation of Ataxin-1 revealed a new regulatory principle: non-coding RNAs can direct DZIP3 substrate specificity.

   Evidence RNA pulldown, Co-IP, in vitro ubiquitylation reconstitution, knockdown/overexpression with protein stability readout in senescent cells

   PMID:24326307

   Open questions at the time

   • Ubiquitin chain linkage type on Ataxin-1 was not specified
   • Whether other lncRNAs similarly regulate DZIP3 substrate targeting remained open
   • In vivo relevance of HOTAIR-DZIP3 axis beyond senescence was not tested
4. 2015 High

   Genome-wide studies in mouse ES cells extended the H2AK119 ubiquitylation role to developmental gene regulation and showed that DZIP3 reorganizes 3D chromatin conformation at its target loci, distinguishing its target set from the canonical PRC1 component Ring1B.

   Evidence ChIP-seq, Hi-C chromatin conformation analysis, knockdown with transcriptomics in mES cells

   PMID:26568260

   Open questions at the time

   • Mechanism by which DZIP3 alters 3D chromatin architecture was not elucidated
   • Whether DZIP3 cooperates with or substitutes for PRC1 complexes at shared targets was unresolved
5. 2015 High

   Identification of DZIP3 as an ERα coactivator that enhances GRIP1–CARM1 interaction independently of its E3 ligase activity revealed a non-catalytic transcriptional function, expanding its role beyond ubiquitination.

   Evidence Yeast two-hybrid, Co-IP, ERα reporter assay, ChIP at ERE-containing promoters, siRNA knockdown with qRT-PCR in breast cancer cells

   PMID:26505218

   Open questions at the time

   • How ligase-dependent and ligase-independent functions of DZIP3 are coordinated in the same cell was unknown
   • Whether DZIP3 coactivator function extends to other nuclear receptors was not tested
6. 2020 High

   The dual mechanism by which DZIP3 stabilizes Cyclin D1 — binding its mRNA 3′ UTR via the lysine-rich region and catalyzing K63-linked ubiquitination of Cyclin D1 protein via the RING domain — demonstrated that its RNA-binding and ligase activities can converge on the same target to drive G1 cell-cycle progression and tumorigenesis.

   Evidence RIP, Co-IP, in vitro ubiquitylation with K63-linkage specificity, domain mutagenesis, flow cytometry for G1 arrest, mouse and zebrafish xenograft models

   PMID:33067265

   Open questions at the time

   • Whether other DZIP3 targets are similarly regulated at both mRNA and protein levels was unknown
   • Structural basis for how the lysine-rich region recognizes AU-rich elements was not determined
7. 2020 Medium

   Showing that DZIP3 targets GBP5 for K48-linked ubiquitination and proteasomal degradation upon RSV G protein induction established DZIP3 as an innate immune modulator and demonstrated its capacity for K48-linked chain assembly alongside its K63-linked activity.

   Evidence Overexpression/knockdown with K48-linkage-specific ubiquitination assay, proteasome inhibitor rescue in virus-infected cells

   PMID:32796072

   Open questions at the time

   • Whether DZIP3 directly ubiquitinates GBP5 or acts through an intermediate was not fully resolved
   • Single-lab finding without independent replication
   • Broader role in antiviral innate immunity beyond RSV was not explored
8. 2023 Medium

   Proteomic identification of the DZIP3 interactome in gastric cancer cells revealed an association with the CUL4B complex and downstream regulation of SETD7 and ZBTB4, suggesting DZIP3 may participate in multi-E3-ligase assemblies.

   Evidence Co-IP/mass spectrometry, RNA-seq, siRNA knockdown with proliferation and invasion assays in gastric cancer cells

   PMID:36841324

   Open questions at the time

   • Functional significance of the CUL4B interaction (direct subunit vs. transient association) was not dissected
   • Whether SETD7 and ZBTB4 are direct ubiquitination substrates was not established
   • Single-lab study in one cancer type
9. 2026 Medium

   The finding that lncRNA LINCMD1 sequesters DZIP3 in the nucleus to prevent K48-linked ubiquitination and degradation of cytoplasmic OCTN2 established a second lncRNA-based regulatory mechanism and showed that DZIP3 subcellular partitioning controls substrate access.

   Evidence Co-IP, subcellular fractionation, K48-linkage ubiquitination assay, RNA pulldown, antisense oligonucleotide rescue in vivo in MASH-HCC model

   PMID:41566533

   Open questions at the time

   • Single-lab finding, awaiting independent validation
   • Whether nuclear sequestration by LINCMD1 simultaneously affects DZIP3 chromatin functions was not examined
   • Generalizability of lncRNA-mediated compartmental regulation of DZIP3 beyond LINCMD1 and HOTAIR is unknown

• A unifying model explaining how DZIP3 selects among its diverse ubiquitin chain types (mono, K48, K63) for different substrates, and how its RNA-binding, chromatin, and coactivator functions are spatiotemporally coordinated, remains to be established.
• No structural model of DZIP3 exists to explain linkage-type specificity or RNA recognition
• The E2 ubiquitin-conjugating enzymes that partner with DZIP3 for each chain type are not identified
• How DZIP3 is partitioned between cytoplasmic mRNA regulation, nuclear chromatin modification, and coactivator functions in the same cell is unresolved